JCU Corporation

Investment Thesis Overview

JCU Corporation is a dominant niche player in electroplating chemicals, holding ~60%+ global market share in PCB copper via-fill chemicals. The company benefits from three powerful structural tailwinds: (1) AI-driven semiconductor advanced packaging demand, (2) the "China+1" supply chain diversification trend across Southeast Asia, and (3) improving capital returns with a new 50% total payout ratio target. We initiate coverage with a BUY rating and a target price of ¥9,500 (25x FY2027E EPS of ¥380), representing 53% upside from current levels.

Anomaly 1: Net Profit Declined Despite Revenue Growth (FY2023)

Deviation: Revenue grew +11.9% but net profit declined 5.6%. Shortfall of ~¥1,100M vs. expected.

Root cause: Two below-the-line items: (1) Equity method loss surged 4x (¥115M → ¥474M); (2) Deferred tax adjustment exploded (¥63M → ¥600M) due to deferred tax liabilities on overseas subsidiaries' retained earnings. Effective tax rate rose to 36.8% from 30.8%.

Assessment: Temporary, non-operating headwind. No structural issue.

Anomaly 2: Revenue & Segment Profit Trough (FY2024)

Deviation: Revenue -8.4% after two years of growth. Chemical segment profit -13.9%.

Root cause: Post-pandemic inventory correction across the electronics supply chain. Smartphone/PCB demand remained globally weak after the "stay-at-home demand bubble" burst.

Assessment: Cyclical trough; recovery confirmed in FY2025-FY2026.

Anomaly 3: Extreme Equipment Business Cyclicality

Deviation: Equipment revenue swung from +99.5% (FY2023) to -34.7% (FY2026). Segment profit -44.2% in FY2026.

Root cause: Order-driven project model. FY2025 order backlog dropped 69.2% (¥4,234M → ¥1,303M), signaling FY2026 crash. Backlog cover fell from 1.33x to 0.14x.

Assessment: Inherently lumpy business; strategically important for chemical pull-through but not a core profit driver.

Anomaly 4: Net Margin Compression to 22.2% (FY2023-FY2024)

Deviation: Net margin compressed from 26.3% (FY2022) to 22.2% for two consecutive years.

Root cause: Driven by non-operating items (equity method losses, deferred tax) in FY2023 and operating deleverage in FY2024 (SG&A % rose as revenue declined). Recovery to 30.6% in FY2026 confirms these were temporary.

Anomaly 5: Dividend Growth Outpacing EPS Growth

Deviation: DPS grew +66.7% (5yr) vs. EPS +50.0%. Payout ratio rose from 23.4% to 32.3% peak.

Root cause: Explicit policy of "stable dividend increases" (安定的な増配). Management raised dividends every year regardless of earnings volatility. The new 50% total payout ratio target provides headroom for continued increases.

Anomaly 6: Strong Recovery — OP Margin Expanding to 41.0%

Deviation: Operating margin expanded +8.7pp over two years from 32.3% trough to 41.0%.

Root cause: AI/server demand became a new growth driver; inventory correction cycle ended. Chemical Business showed significant operating leverage: +11-12% revenue growth translated to +19-27% profit growth.

Anomaly 7: Gross Margin Expansion (64.8% → 69.5%)

Deviation: Gross margin improved +4.7pp over 5 years, reaching 69.5% in FY2026.

Root cause: Operating leverage, favorable product mix shift to semiconductor chemicals, JPY weakness tailwind, and raw material cost stabilization.

Anomaly 8: FCF Collapse from ¥6.1bn to ¥0.7bn

Deviation: FCF declined 89% from peak (¥7.5bn in FY2023) to trough (¥688mn in FY2026).

Root cause: Strategic investment cycle under JCU VISION 2035. Kumamoto facility (¥6,526M) + land for new research lab (¥1,028M) + experimental equipment (¥429M).

Assessment: Self-funded (no debt increase; equity ratio 87.1%). Temporary compression by design. FCF should rebound sharply post-FY2026.

Profit Quality Assessment

JCU demonstrates high-quality earnings characterized by:

• Cash conversion: Operating CF of ¥9.0bn (FY2026) covers net profit of ¥9.1bn (99% conversion), indicating earnings are cash-based, not accrual-driven
• Balance sheet strength: Zero net debt (0.01x D/E), ¥23.88bn net cash, 87.1% equity ratio — one of the strongest balance sheets in Japanese specialty chemicals
• Recurring revenue: ~70-80% of chemical revenue is recurring consumables, supporting earnings visibility
• Margin sustainability: Gross margin of 69.5% and OP margin of 41.0% are supported by proprietary technology and high switching costs
• Capital allocation improving: New 50% total payout ratio target signals commitment to shareholder returns
• FCF rebound expected: Post-FY2026 capex peak, FCF should normalize to ¥5-7bn range, supporting further dividend increases

Rating Rationale

JCU offers a favorable risk/reward profile for investors seeking exposure to the AI and semiconductor supply chain with downside protection from a fortress balance sheet. The stock's current valuation (~17x PER, ~2.8x PBR) does not fully reflect the structural margin improvement (Chemical OP margin from 38.9% to 47.2%) and the improving capital returns profile. As the Kumamoto depreciation headwind fades and FCF rebounds in FY2027-FY2028, we expect the market to re-rate the stock closer to global peer multiples of 25-30x.

Target price methodology: 25x FY2027E EPS of ¥380 = ¥9,500. The 25x multiple is a discount to global specialty chemical peers (25-30x) reflecting Japan small-cap discount and near-term depreciation headwind, but a premium to JCU's 5-year average (~18x) justified by structurally higher margins and AI tailwinds.